Robust T cell Responses Reported Across Diverse HLA backgrounds in Ph 2 AMPLIFY-7P Trial of ELI-002
Robert Connelly, Chief Executive Officer of Elicio, commented, “We are extremely pleased to see that mKRAS-specific T cell responses are induced among patients with a diverse HLA background, suggesting that ELI-002 7P may be applicable to a broad range of PDAC patients potentially addressing a key unmet need and expanding the potential market opportunity. Our observations build on past data to show that the majority of patients express mKRAS-presenting HLAs, likely enabling T cell recognition in most patients. These encouraging findings highlight the potential for ELI-002 7P to benefit a broader spectrum of PDAC patients, which may extend the reach of immunotherapy to more individuals and address a critical unmet need.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the